Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Double-crane Pharmaceutical Seeks More Acquisitions

This article was originally published in PharmAsia News

Executive Summary

Beijing Double-crane Pharmaceutical has disclosed plans to achieve by 2010 revenue of 8 billion yuan. Of this, pharmaceutical income will contribute to 5 billion yuan, double the 2.2 billion yuan earned in 2007. Parent company Beijing Pharmaceutical Group has announced that it will increase sales to 30 billion yuan by 2010 from 20.45 billion yuan in 2007; this means key subsidiary Double-crane will need to greatly improve its performance to reach its target. Double-crane is approaching several firms with complementary business for possible acquisitions. An analyst notes that the company will probably look at intravenous product makers to further reinforce its number one position in the sector. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts